Filter Results:
(617)
Show Results For
- All HBS Web
(617)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
Show Results For
- All HBS Web
(617)
- People (2)
- News (55)
- Research (446)
- Events (2)
- Multimedia (8)
- Faculty Publications (391)
- 01 Jun 2000
- News
Managing the Map
We are at the dawn of a new epoch in the world of science, one that will cast strong light on a unique corner of the biotechnology field known as genomics. The designation refers to the study of genes, those chemical building blocks of... View Details
Keywords: Peter K. Jacobs
- 12 Sep 2006
- First Look
First Look: September 12, 2006
alliance contracts, all of which concern early-stage research at small, biotechnology R&D companies. Staged investment is ubiquitous, but solutions to agency problems vary. The cycle of equity participation in alliances resembles what... View Details
Keywords: Sean Silverthorne
- 30 Mar 2021
- Working Paper Summaries
Kidney Exchange: An Operations Perspective
- April 1995
- Teaching Note
Genzyme Corporation: A Financing History (TN)
By: Timothy A. Luehrman
Teaching Note for (9-294-005). View Details
Keywords: Biotechnology Industry
- March 2024
- Case
Biomanufacturing Decentralization by Stämm
By: Paul A. Gompers, Jenyfeer Martínez Buitrago and Mariana Cal
In Buenos Aires, Argentina, cousins Llamazares and D’Alvia founded Stämm, a startup based on the idea of decentralizing biomanufacturing processes and downsizing biotech facilities. After raising its seed and series A rounds, and while finalizing its series B round in... View Details
Keywords: Business Model; Business Startups; Entrepreneurship; Venture Capital; Selection and Staffing; Technological Innovation; Science-Based Business; Business Strategy; Commercialization; Growth and Development Strategy; Product Launch; Research and Development; Biotechnology Industry; Latin America; South America; Argentina; Buenos Aires
Gompers, Paul A., Jenyfeer Martínez Buitrago, and Mariana Cal. "Biomanufacturing Decentralization by Stämm." Harvard Business School Case 824-190, March 2024.
- October 2023 (Revised May 2024)
- Case
Thermo Fisher Scientific: Foray into Contract Research
By: Satish Tadikonda, William Marks and Kevin Emancipator
After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details
Keywords: Mergers and Acquisitions; Customer Focus and Relationships; Corporate Strategy; Organizational Change and Adaptation; Biotechnology Industry
Tadikonda, Satish, William Marks, and Kevin Emancipator. "Thermo Fisher Scientific: Foray into Contract Research." Harvard Business School Case 824-073, October 2023. (Revised May 2024.)
- November 2016 (Revised December 2016)
- Supplement
Anthony Starks at InSiL Therapeutics (B)
By: Vicki Sato and Gary Pisano
This case accompanies the (A) case from Anthony Starks's perspective. View Details
Keywords: Biotech; Management Challenges; R&D; R&D Project Management; Management; Biotechnology Industry; California
Sato, Vicki, and Gary Pisano. "Anthony Starks at InSiL Therapeutics (B)." Harvard Business School Supplement 617-030, November 2016. (Revised December 2016.)
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would... View Details
Keywords: Genetics; Business Growth and Maturation; Business Plan; Competition; Venture Capital; Biotechnology Industry
Hamermesh, Richard G., Mara Aspinall, and Phillip Andrews. "Gene Sequencing: Staking a Position in an Expanding Industry." Harvard Business School Case 812-004, October 2011.
- October 2009 (Revised January 2014)
- Teaching Note
Sustainability at Millipore (TN)
Teaching Note for [610012]. View Details
- September 2008 (Revised April 2009)
- Supplement
Kevin Sharer at Amgen: Sustaining the High-Growth Company (B)
By: William W. George
Kevin Sharer, CEO of Amgen, is assessing the challenges he has faced as a major product came under regulatory scrutiny. View Details
Keywords: Governing Rules, Regulations, and Reforms; Leadership; Product Development; Biotechnology Industry
George, William W. "Kevin Sharer at Amgen: Sustaining the High-Growth Company (B)." Harvard Business School Supplement 409-037, September 2008. (Revised April 2009.)
- 2009
- Working Paper
Social Influence Given (Partially) Deliberate Matching: Career Imprints in the Creation of Academic Entrepreneurs
By: Pierre Azoulay, Christopher C. Liu and Toby E. Stuart
Actors often match with associates on a small set of dimensions that matter most for the particular relationship at hand. In so doing, they are exposed to unanticipated social influences because counterparts have more interests, attitudes, and preferences than would-be... View Details
Keywords: Entrepreneurship; Patents; Marketplace Matching; Mathematical Methods; Science-Based Business; Power and Influence; Social and Collaborative Networks; Biotechnology Industry
Azoulay, Pierre, Christopher C. Liu, and Toby E. Stuart. "Social Influence Given (Partially) Deliberate Matching: Career Imprints in the Creation of Academic Entrepreneurs." Harvard Business School Working Paper, No. 09-136, May 2009.
- September 2003 (Revised March 2007)
- Case
Direvo Biotech AG
Describes the financing and growth decisions facing Direvo, a young German biotech firm with a customer/partner that wants to become an investor. Also discusses the business model for Direvo's directed evolution technology, with applications in both industrial enzymes... View Details
Keywords: Business Model; Decisions; Business Exit or Shutdown; Value; Business Startups; Biotechnology Industry; Germany
Roberts, Michael J., Vincent Dessain, and Anders Sjoman. "Direvo Biotech AG." Harvard Business School Case 804-017, September 2003. (Revised March 2007.)
- April 2002
- Teaching Note
Anagene, Inc. TN
By: Robert S. Kaplan
Teaching Note for (9-102-030). View Details
- October 2001 (Revised March 2002)
- Case
Perlegen Sciences
By: Linda A. Hill and Nicole Tempest
As a biotech start-up company involved in studying human genomes, Perlegen needed to develop an organization that fostered innovation and teamwork among a group of highly trained professionals from both the science and technology fields. Perlegen's CEO, Brad Margus,... View Details
Keywords: Innovation Leadership; Groups and Teams; Management Teams; Problems and Challenges; Business Startups; Genetics; Talent and Talent Management; Innovation Strategy; Biotechnology Industry
Hill, Linda A., and Nicole Tempest. "Perlegen Sciences." Harvard Business School Case 402-026, October 2001. (Revised March 2002.)
- August 1985 (Revised May 1986)
- Case
BioTechnica International
By: Ray A. Goldberg
Keywords: Biotechnology Industry
Goldberg, Ray A. "BioTechnica International." Harvard Business School Case 586-014, August 1985. (Revised May 1986.)
- November 1995 (Revised March 1996)
- Case
Ares-Serono (Abridged)
By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop
Keywords: Biotechnology Industry
Yoshino, Michael Y., Jean-Pierre Jeannet, and Carin-Isabel Knoop. "Ares-Serono (Abridged)." Harvard Business School Case 396-104, November 1995. (Revised March 1996.)
- 01 Sep 2020
- Cold Call Podcast
How to Launch a New Biosciences Product: Start Small or Dive in?
- 01 Nov 2024
- In Practice
Layoffs Surging in a Strong Economy? Advice for Navigating Uncertain Times
decision about entrepreneurship Starting your own company after a layoff is a significant decision. While it may seem like an opportune time, research suggests there are some important considerations. “Entrepreneurs coming from high-tech sectors such as View Details
- 01 Dec 2003
- News
The Next Big Thing
research and commercialization of biotechnology and biomedicine, the life sciences’ core activities? And what steps must be taken to maintain preeminence? In a keynote presentation at a September “Massachusetts Life Sciences Summit,” HBS... View Details
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
is a lot other work at the school going on around these issues by many other faculty. For instance, Dave Scharfstein is doing great work on how capital market forces influence the development strategies of biotechnology companies. David... View Details